iJRASET

International Journal For Research in
Applied Science and Engineering Technology

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 9 Issue: VII Month of publication: July 2021

DOI: <https://doi.org/10.22214/ijraset.2021.36829>

www.ijraset.com

Call: 08813907089

E-mail ID: ijraset@gmail.com

Molecular Docking Study of Alzheimer Disease Responsible Protein Inhibition Activity by Bioactive Ginkgolides

Ashish Kumar Swami¹, Sangita Sharma²

^{1, 2}Department of Chemistry, Hemchandracharya North Gujarat University, Patan-384265, Gujarat, India

Structured Abstract: Terpenoids are major components present in herbal formulations of *Ginkgo biloba* which are considered to slow down progression of Alzheimer disease. Ginkgolide A, Ginkgolide B, Ginkgolide C, Ginkgolide M, Ginkgolide J, Ginkgolide K and Bilobalide are some of the terpenoids selected for computational theoretical calculations using DFT theory at B3LYP/6-311+G*(d,p) basic set level using Gaussian 16W. To study the interaction between selected terpenoids and selected proteins, molecular docking analysis is carried out using Argus Lab (4.0.1) and Auto Dock (4.2). Calculations are carried out on efficient shape-based search algorithm principle and a score base function to calculate the binding energies between them. ADMET analysis provide properties insight of terpenoids compounds. Results from calculated data reveal that there are possible interactions. This data can help in development of potent protein kinase inhibitor for the treatment of Alzheimer.

Keywords: Alzheimer Disease; Terpenoid; DFT; Molecular Docking; Binding Energies; Inhibition; Drug Likeness

I. INTRODUCTION

Ginkgo biloba is a living fossil, it is the only survivor of one of the species originated 150 million years ago. Its components in modern science has been identified for the reasons of immutability.[1] *Ginkgo biloba* have been used as herbal medicine or dietary supplements for treatment of heart disease, eye ailments, tinnitus, cerebral and peripheral vascular insufficiency, injuries involving brain trauma, dementia, short-term memory improvement, cognitive disorders secondary to depression, vertigo, and various cognitive disorders.[2]

Leaves and root bark contain terpenoids, including the monomethyl-mononor diterpenes: Ginkgolide A, Ginkgolide B, Ginkgolide C but Ginkgolide M are found in the root bark; Ginkgolide J, pene Bilobalide in the leaves. Ginkgolides are reported to be antidepressant and antistress effects in different animal models, these appear to be mediated by antagonism of the GABA receptor and show elevating brain catechol amines and plasma corticosterone levels.[3],[4]

Alzheimer Disease marked by a gradual loss of cognitive functioning which can also incorporate losses of motor, emotional, and social functioning as well. It is a permanent and progressive disease that eventually renders people unable to care for themselves.[5] Till time, there is no particular cure method available for AD, but the pathogenesis of the disease could be delayed by the use of natural antioxidants drugs.[6]

In most high-income country settings, where only around 50% of people living with Alzheimer's receive a diagnosis. In low and middle-income countries, less than 10% of cases are diagnosed. As populations age, due to increasing life expectancy, the number of people with AD is increasing.[7] It is estimate that there will be 50 million people worldwide living with Alzheimer's in 2015. Every year, nearly 10 million new cases are added, implying that 1 new case every 3 seconds and expected to rise to 82 million by 2030.[8-10]

In many articles, research papers and reports suggest that there is a direct physical interaction happen between proteins and antioxidant drug compound. Antioxidant drug compound binds to the protein which reduced neurological disorder activity and free radical generation.[11]

The structures of Ginkgolides A, B, C, J, and M only differ by the number and the position of hydroxyl groups on C1, C3, or C7 of the spirononane framework. In figure I and Table I show Ginkgolides how do defer its name on the basis of the position of hydroxyl groups position on R1, R2, and R3. Figure II is Bilobalide compound.[12-17]

Table I Positioning of Group OH and H in Ginkgolides

Name	R ₁	R ₂	R ₃
Ginkgolide A	OH	H	H
Ginkgolide B	OH	OH	H
Ginkgolide C	OH	OH	OH
Ginkgolide J	OH	H	OH
Ginkgolide M	H	OH	OH
Ginkgolide K	-	OH	H

Figure I. Basic structure of ginkgolide with group position

Figure II. Structure of bilobalide

II. MATERIAL AND METHODS

A. Software Used

Gaussian 16W package[18]

Gauss view 6.0[19]

Molecular graphics laboratory (MGL) tools Package (accessed March 14, 2020)

PMV- Python 2.7- language was downloaded from www.python.com(accessed March 17, 2020).[20]

MSMs- MSMS library is used by the Pmv module msms Commands[21]

PCVolRen- The PCVolRen library is used in the PMV module[22]

ADT- AutoDock4.2.6. was downloaded from www.scripps.edu (accessed March 14, 2020)[23]

Isocontour- The isocontour library is used by the Pmv module[24]

Vision- Vision Software is a visual-programming environment[25]

Cygwin (a data storage) c:\program and Python 2.7 were simultaneously downloaded from www.cygwin.com(accessed March 14, 2020)[26]

Argus lab (4.0.1) was downloaded from <http://www.arguslab.com/arguslab.com/ArgusLab.html>(accessed March 7, 2020)[27]

B. Preparation and Optimization of Terpenoids

Chemical 3D structures of the selected terpenoids namely Ginkgolide A, Ginkgolide B, Ginkgolide C, Ginkgolide M, Ginkgolide J, Ginkgolide K and Bilobalide were retrieved from the Pub Chem database[28] and were optimized in Gaussian 16W software[18] using Density Functional Theory (DFT) by Becke gradient corrected exchange functional[29] and Lee-Yang-Parr correlation functional[30] with three parameters B3LYP method at 6-31+G* basis set level[31] Optimized structure of selected terpenoids were subjected to arrange energy minimization using Auto dock and Argus lab.

C. Preparation of Protein Structures

The solution structure of the β -amyloid protein A β -peptide chain (1–42) (PDB ID: 1IYT) and Binary complex structure of human tau protein kinase (PDB ID: 1J1C) was retrieved from the RCSB Protein Data Bank (PDB)[32] and necessary changes like removal of water molecules, extra chains and heteroatoms were done using 'Prepare Protein' module of Auto Dock 4.2.6.[23]and Argus Lab 4.0.1[27]

D. Pharmacokinetic Analyses of Ligands

The pharmacokinetic profile of the selected terpenoids was determined by optimizing their ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) clarification properties using swiss ADME[33] server online and toxicity calculated from PreADMET[34] server online data shown in Table II.

E. Drug Likeness Assessment

Insilco methods are computer-based methods widely used in the pharmacological field of science to help discover inhibitors with high binding capabilities with a protein target, drug-likeness properties.[35] Other drug likeness rules like Lipinski's rule[36], Veber rule[37], MDDR-like rule[38], Ghose filter[39], BBB rule[40], CMC-50[41] and Quantitative Estimate of Drug-likeness (QED)[42] like rule are also applied. Drug-like properties of the selected terpenoids, were analyzed on the basis of physical properties, namely molecular weight (Mol.wt.), partition coefficient (AlogP), number of hydrogen bond acceptors (Num H acceptor) and number of hydrogen bond donors (Num H donor).[43]

F. Molecular Docking

The selected seven terpenoids with neuroprotective properties were subjected to molecular docking with both the targets, namely B-amyloid A β -peptide (1–42) and Tau protein kinase using Argus lab and Auto Dock 4.2.6. Best conformations were generated using the genetic algorithm for each compound in Auto dock and Argus lab software. Auto Dock 4.2.6 estimates binding energy and inhibitory constant of the ligands with respect to their targets on the basis of Lamarckian genetic algorithm.[44] The binding free energy was empirically calculated based on the energy terms and a set of coefficient factors. A three-dimensional grid of interaction energy was calculated using Auto Grid based on the macromolecular coordinates and the docking simulations were performed using Auto Dock 4.2.6. The binding energy and inhibition constant (Ki) are expressed as kcal/mol and micromolar (μ m), respectively and was used to rank the docking positions of the terpenoids.[45] All analysis was done at 298.15 K temperature and proteins molecules were considered in rigid form and terpenoids in flexible form during docking. In this molecular docking analysis, there are some of the same residues take participated in both software. But we found binding energy level data are different.

1) *Argus Lab*: Docking with Argus software was that 1IYT protein kinase of β -amyloid protein as targeted at DEF binding site with selected residue of amino acid like 21ALA, 23ASP, 22GLU, 25GLY, 17LEU, 16LSY, 19PHE, 20PHE, 18VAL, 24VAL interacting with selected terpenoids and a new pose are garneted with specific values of energy. Binding site is selected with Site Box 30 x 30 x 30 angstroms dimensional and with 0.4 Grid resolution. For the AScore scoring function and ascore.prm parameter set was used to study this binding process. Docking engine generated energy data on the basis of Lamarckian Genetic Algorithm.

Similarly, 1j1c protein kinase of tau-protein was targeted at ADP binding site of chain-A amino acid. This amino acid has 83 ALA, 141 ARG, 64 ASN, 186 ASN, 133 ASP, 200 ASP, 185 GLN, 65 GLY, 62 ILE, 132 LEU, 188 LEU, 85 LYS, 67 PHE, 66 SER, 134 TYR, 110 VAL, 135 VAL and 431 MG residue where interacted with seven terpenoid. All other selected parameter like scoring function, grid resolution, parameter set, binding site box dimensions and dock engine are same as used in case of β -amyloid protein.

- 2) *Auto Dock*: In auto dock software, the selected conditions are same as used in Argus lab software except site box size 110 x 110 x 110 angstroms and Grid resolution with volume of 1.0. When docked with selected terpenoids, 1j1c-kinase protein residues were not exactly same but are namely HIS 13, GLY 9, VAL 12, HIS 14, TYR 10, GLN 15, LYS 16, PHE 19, TYR 10, ASP 7, GLU3, GLU11, HIS 6, LEU 17, PHE 20, ALA 21, DEF 85, VAL 24, GLY 25, MET 35, LYS 28.

In case of tau protein 1j1c kinase residues again change as new residues are ADP 930, MG 931, GLN 685, PHE 360, ARG 383, THR 356, PRO 357, ARG 720, GLN 765, GLY 759, ASP 760, SER 761, ARG 220, ARG 723, TYR 716, GLY 762, GLN 265, GLY 262, ILE 228, TYR 517, LYS 594, PHE 523, VAL 626, LYS 591, PHE 67, VAL 69, LYS 86, GLY 68, TYR 127, LYS 771, GLN 599, LYS 594, LYS 591, TYR 617, LYS 123, GLU 125, LEU 88, GLN 795, ASP 90, LYS 91, and GLN 89 and that show interaction with terpenoids.

III. RESULTS AND DISCUSSION

β -amyloid protein A β -peptide (1–42) chain, a major component of amyloid plaques accumulates in neurons of AD brains.[46] Biochemical analysis of the amyloid peptides isolated from Alzheimer's disease brain indicates that β -amyloid protein A β -peptide (1–42) chain is the principal species associated with senile plaque amyloids, while β -amyloid (1-40) chain is more abundant in cerebrovascular amyloid deposit.[47] Tau proteins is member of microtubule associated with proteins this family. Microtubule-stabilizing protein abundant in neurons of the CNS. The tau abnormal function leads to neurodegenerative disorders. Tau is a phosphoprotein with 79 potential serine (Ser) and threonine (Thr) phosphorylation sites on the longest tau isoform. Phosphorylation has been reported on approximately 30 of these sites in normal tau proteins.[48] Understand computationally and biologically study of genetically programmed molecular mechanism that may help in the development of new therapeutic methods as well as in identification of antioxidant compound for finding a cure of AD.[49],[50] Therapeutic advancement approaches in AD study has provided better results of interaction with target molecules with its best physicochemical properties of selected drugs.[51] Proteins inhibitory activity leads antioxidant drug protease neurological disorders. This study checks the inhibition of proteins through computational theoretical analysis. Selected terpenoids compounds play vital role in finding of binding interface between the receptor and ligands.[52]

A. ADMET Analyses Rule

The ADMET descriptors used to describe these properties include aqueous solubility, blood–brain barrier penetration, CYP2D6 binding, human intestinal absorption, plasma protein binding (PPB) and hepatotoxicity and ADMET prediction for selected terpenoids are shown in Table II.

In this Table II calculated data are Presented in five parts (1) Physiochemical Properties (2) Lipophilicity (3) Water solubility (4) Pharmacokinetics (5) Druglikeness.[53]

As for as Drug likeness rules are considered five different rules are applied to selected seven terpenoids. All the seven terpenoids fulfill all the conditions of Lipinski's rules except GC which does not follow second condition. In case of veber rules all terpenoids follow first condition but second condition followed by GA, GK and BB while other does not follow.

MDDR-like rule is followed by all terpenoids considering its all condition. In case of Ghose filter rule GM and BB do not follow first condition but all other condition is followed by all the selected terpenoids. In case of BBB rule all terpenoids successfully fill to three condition of the rule.

CMC-50 rule is fully followed by all the selected compounds. QED rules is combination of eight characteristics condition which are already studied in above mention rules. All the terpenoids are drug like on the basis of in silico studies fulfill ADMET criteria and thus could subsequently be further experimentally screened using in vitro or in vivo strategies for new potential tool for further research study for AD.[54]

Table II. Admet Properties Calculation ^{[34],[35], [55], [56], [57],[87]}

Physiochemical Properties									References
Sr.No.	Terpenoids	BB ^[a]	GA ^[b]	GB ^[c]	GC ^[d]	GJ ^[e]	GM ^[f]	GK ^[g]	
1	Formula	C ₁₅ H ₁₈ O ₈	C ₂₀ H ₂₄ O ₉	C ₂₀ H ₂₄ O ₁₀	C ₂₀ H ₂₄ O ₁₁	C ₂₀ H ₂₄ O ₁₀	C ₂₀ H ₂₄ O ₁₀	C ₂₀ H ₂₂ O ₉	
2	Molecular Weight	326.3	408.4	424.4	440.4	424.4	424.4	406.38	[58]
3	#Heavy atoms	23	29	30	31	30	30	29	[58]
4	#Aromatic heavy atoms	0	0	0	0	0	0	0	[58]
5	Fraction Csp ³ ^[h]	0.8	0.85	0.85	0.85	0.85	0.85	0.75	
6	#Rotatable bonds	1	1	1	1	1	1	1	[58]
7	#H-bond acceptors	8	9	10	11	10	10	9	[58]
8	#H-bond donors	2	2	3	4	3	3	2	[58]
9	MR ^[i]	71.2	92.13	93.29	94.45	93.29	93.25	91.62	[58]
10	TPSA ^[j]	119.36	128.59	148.82	169.05	148.82	148.82	128.59	[59]
11	Number of Electrons	172	216	224	232	224	224	216	
Lipophilicity									
12	iLOGP ^[k]	0.81	1.12	1.63	0.93	1.23	0.72	1.7	[60]
13	XLOGP ³ ^[l]	-0.27	0.59	-0.38	-1.36	-0.38	-0.3	0.1	[61]
14	WLOGP ^[m]	-0.74	-0.34	-1.37	-2.4	-1.37	-1.51	-0.42	[62]
15	MLOGP ^[n]	0.42	0.83	0.06	-0.7	0.06	0.06	0.74	[63],[64]
16	Silicos-IT Log P ^[o]	0.57	0.81	-0.07	-0.96	-0.07	-0.47	0.8	[65]
17	Consensus Log P ^[p]	0.16	0.6	-0.03	-0.9	-0.11	-0.3	0.58	[66]
Water solubility									
18	ESOL Log S ^[q]	-1.63	-2.68	-2.17	-1.65	-2.17	-2.22	-2.36	[67]
19	ESOL Solubility (mg/ml)	7.7	0.858	2.9	9.91	2.9	2.58	1.79	[67]
20	ESOL Solubility (mol/l)	0.0236	0.0021	0.00683	0.0225	0.00683	0.00608	0.0044	[67]
21	ESOL Class	Very soluble	Soluble	Soluble	Very soluble	Soluble	Soluble	Soluble	[67]
22	Ali Log S ^[r]	-1.78	-2.86	-2.28	-1.69	-2.28	-2.37	-2.36	[68]
23	Ali Solubility (mg/ml)	5.45	0.559	2.22	8.99	2.22	1.83	1.79	[68]
24	Ali Solubility (mol/l)	0.0167	0.00137	0.00522	0.0204	0.00522	0.00431	0.00441	[68]
25	Ali Class	Very soluble	Soluble	Soluble	Very soluble	Soluble	Soluble	Soluble	[68]
26	Silicos-IT LogSw	-1.12	-1.59	-0.77	0.06	-0.77	-0.32	-1.57	[65]
27	Silicos-IT Solubility (mg/ml)	24.8	10.6	72.7	500	72.7	205	11	[65]
28	Silicos-IT Solubility (mol/l)	0.0759	0.0259	0.171	1.14	0.171	0.483	0.027	[65]
29	Silicos-IT class	Soluble	Soluble	Soluble	Soluble	Soluble	Soluble	Soluble	[65]
Pharmacokinetics									
30	GI absorption ^[s]	High	High	Low	Low	Low	Low	High	[69]
31	BBB permeant ^[t]	No	No	No	No	No	No	No	[36]
32	Pgp substrate ^[u]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	[70]
33	CYP1A2 ^[v] inhibitor	No	No	No	No	No	No	No	[71],[76],[77]
34	CYP2C19 ^[w] inhibitor	No	No	No	No	No	No	No	[72],[76],[77]
35	CYP2C9 ^[x]	No	No	No	No	No	No	No	[73],[76],[77]

	inhibitor								
36	CYP2D6 ^[y] inhibitor	No	No	No	No	No	No	No	[74],[76],[77]
37	CYP3A4 ^[z] inhibitor	No	No	No	No	No	No	No	[75],[76],[77]
38	log Kp (cm/s) ^[aa]	-8.48	-8.37	-9.16	-9.95	-9.16	-9.1	-8.71	[78]
Druglikness									
39	Lipinski #violations	Yes; 0 violation	Yes; 0 violation	Yes; 0 violation	No; 1 violation	Yes; 0 violation	Yes; 0 violation	Yes; 0 violation	[36]
40	Ghose #violations	No; 1 violation	Yes; 0 violation	No; 1 violation	No; 1 violation	No; 1 violation	No; 1 violation	No; 1 violation	[39]
41	Veber #violations	Yes; 0 violation	Yes; 0 violation	No; 1 violation	No; 1 violation	No; 1 violation	No; 1 violation	Yes; 0 violation	[37]
42	Egan #violations	Yes; 0 violation	Yes; 0 violation	No; 1 violation	No; 1 violation	No; 1 violation	No; 1 violation	Yes; 0 violation	[79]
43	Muegge #violations	Yes; 0 violation	Yes; 0 violation	Yes; 0 violation	No; 2 violation	Yes; 0 violation	Yes; 0 violation	Yes; 0 violation	[80]
44	Bioavailability Score	0.55	0.55	0.55	0.55	0.55	0.55	0.55	[81]
45	PAINS #alerts	Zero alert	Zero alert	Zero alert	Zero alert	Zero alert	Zero alert	Zero alert	[82]
46	Brenk #alerts	1 alert	1 alert	1 alert	1 alert	1 alert	1 alert	1 alert	[41]
47	Leadlikeness #violations	Yes; 0 violation	No; 1 violation	No; 1 violation	No; 1 violation	No; 1 violation	No; 1 violation	No; 1 violation	[83]
48	Synthetic Accessibility(SA)	5.41	6.28	6.38	6.48	6.39	6.42	6.51	[84]
Toxicity									
49	algae_at	0.177817	0.118374	0.157742	0.192339	0.166682	0.201843	0.124129	[85],[86]
50	Ames_test	non- mutagen	non- mutagen	non- mutagen	non- mutagen	non- mutagen	non- mutagen	non- mutagen	
51	Carcino_Mouse	negative	negative	negative	negative	negative	negative	negative	
52	Carcino_Rate	positive	positive	Positive	positive	positive	positive	positive	
53	daphnia_at	2.85214	3.077	2.00595	4.52813	3.06871	2.33042	0.789767	
54	hERG_inhibition	low_risk	low_risk	low_risk	ambiguous	low_risk	low_risk	low_risk	
55	medaka_at	9.75825	11.898	5.61048	27.5974	12.516	7.56479	0.930873	
56	minnow_at	6.79135	4.5476	7.31948	31.3197	8.25605	11.9864	1.36771	
57	TA100_10RLI	negative	negative	negative	negative	negative	negative	negative	
58	TA100_NA	negative	negative	negative	negative	negative	negative	Negative	
59	TA1535_10RLI	negative	negative	negative	negative	negative	negative	Negative	
60	TA1535_NA	negative	negative	negative	negative	negative	negative	Negative	
[a] BB- Bilobalide; [b]GA- Ginkgolide A; [c] GB- Ginkgolide B; [d] GC- Ginkgolide C; [e] GM- Ginkgolide M; [f] GJ- Ginkgolide J; [g] GK- Ginkgolide K; [h] Fraction Csp3-fraction of sp3 carbon; [i] MR- molecular refractivity; [j] TPSA-Topological Polar Surface Area; [k] iLOGP – implicit log P method; [l] XLOGP3- pure atom-additive model ; [m] WLOGP-Water Partition Coefficient; [n] MLOGP- Moriguchi method Partition Coefficient [o] Silicos-IT Log P- FILTER-IT (version 1.0.2) 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html [p] Consensus Log P- n-octanol/water partition coefficient [q] ESOL LogS -Estimated SOLubility Log S; [r] Ali Log S- Ali et al. linked log S with log Po/w [s] GI: Gastro Intestinal [t] BBB: Blood Brain Barrier [u] ; Pgp-P-glycoprotein; [v] CYP1A2: Cytochrome P450 family 1 subfamily A member 2 [w] CYP2C19- cytochrome P450 2C19 [x] CYP2C9-cytochrome P450 2C9 [y] CYP2D6: cytochrome P450 (CYP) 2D6 [z] CYP3A4- Cytochrome P450 3A4 [aa] Log Kp -Skin permeation coefficient.

Figure III. Terpenoids docking interaction in Argus lab software with 1iyt protein kinase (GB interacted with 1iyt)

Figure iv. Terpenoids docking interaction in argus lab software with 1jl1c protein kinase(GC interacted with 1iyt)

B. Docking Analysis

Results calculated from Argus lab 4.0.1 and Auto Dock 4.2.6 are compared in Table III. Figure III and Figure IV show interaction for β -amyloid protein and tau protein in Argus lab software respectively. Binding energy calculated for β -amyloid protein 1iyt kinase interaction level of energy with Argus Lab software between -6.7 to -8.5 kcal. mole⁻¹ and for tau protein 1jl1c kinase interaction level of energy between -5.9 to -9.0 kcal. mole⁻¹. Similarly, the binding energy obtained by that two type of interactions with Auto Dock software are in range of -4.1 to -5.6 kcal. mole⁻¹ for 1iyt kinase of β -amyloid protein and -4.6 to -6.0 kcal. mole⁻¹ for 1jl1c kinase Tau proteins. Here Ginkgolide-J gives highest docking interaction with β -amyloid protein 1iyt kinase is -5.57 kcal. mole⁻¹ and with Tau proteins 1jl1c kinase is -5.95 kcal. mole⁻¹ in Auto Dock Software.

Table III. Docking analysis data of terpenoids with selected proteins.

Sr · N o.	Terpenoids	Docking Score with B-amyloid Kinase- 1iyt			Docking Score with Tau Protein Kinase-1j1c		
		Argus Lab kcal/mol	inhibition constant (Ki)uM (micromolar)	Auto Dock kcal/mol	Argus Lab kcal/mol	inhibition constant (Ki)uM (micromolar)	Auto Dock kcal/mol
1	Ginkgolide A	-7.84651	185.77	-5.09	-7.74157	43.96	-5.94
2	Ginkgolide B	-7.84779	377.73	-4.67	-9.07773	100.79	-5.45
3	Ginkgolide C	-6.73020	244.54	-4.93	-8.69338	407.98	-4.62
4	Ginkgolide J	-6.97580	82.45	-5.57	-5.92464	43.22	-5.95
5	Ginkgolide M	-8.56542	440.86	-4.58	-8.24014	225.33	-4.98
6	Ginkgolide K	-8.05197	102.59	-5.44	-7.06494	102.21	-5.44
7	Bilobalide	-6.92865	962.15	-4.12	-7.24505	110.31	-5.40

In Argus Software, Ginkgolide-M shows highest docking interaction with β -amyloid protein 1iyt kinase is -8.56542 kcal. mole-1 but with Tau proteins 1j1c kinase Ginkgolide-B shows highest docking interaction is -9.07773 kcal. mole-1. In this software study we found auto dock software result are valid as compared than Argus lab software because in every time in Argus lab software we found different value of interaction time, name of residues interaction and values of binding energy. May be this the limitation of Argus software as compare than auto dock software. Both software comparative result study data shown in Graph-I for and Graph-II.

Negative values of binding energy suggest for that interactive behavior with these selected terpenoids and respective site. Generally, in binding process hydrogen bonding and Vander Waal, Covalent, Charge, Polar and Pi-interaction.[88] Many times, a cluster of interactions is also observed, which is seen in our study and shown in figure V and figure VI at the binding sites.

Figure V. Terpenoid docking interaction in autodock software with 1j1c protein kinase (GA interacted with 1j1c)

Figure VI. Terpenoids docking interaction in autodock software with 1j1c protein kinase (BB interacted with 1j1c)

IV. CONCLUSION

All the selected terpenoids show drug likeness character as predicted by ADMET and Drug likeness rule. All the selected terpenoids showed better alignment with active site of all amino acid residues. Binding energy values are negative for all the terpenoids indicating for interaction between β -amyloid and tau proteins kinases. Terpenoids namely Ginkgolide A, Ginkgolide B, Ginkgolide C, Ginkgolide M, Ginkgolide J, Ginkgolide K and Bilobalide may be responsible decreasing Alzheimer's in patients using Ginkgo biloba contents. Auto Dock gives better interaction sites visualization than Argus lab. Auto Dock software gives stability in result data of docking as compared to Argus Lab but these compounds necessary to investigate further research. we should be done clinical trials.

V. LIST OF ABBREVIATIONS

AD- Alzheimer disease
DFT- Density Functional Theory
B3LYP- Becke gradient corrected and Lee-Yang-Parr correlation functional
GABA-Gamma-AminoButyric Acid
MGL- Molecular Graphics Laboratory
3D- Three Dimensional
PDB- Protein Data Bank
ADMET- Absorption, Distribution, Metabolism, Excretion, and Toxicity
MDDR-Modern Drug Data Report
BBB- Blood brain barrier
CMC-50- Comprehensive Medicinal Chemistry drug-like index at 50%
QED- Quantitative Estimate of Drug-likeness
Mol.wt- Molecular Weight
ADP- Adenosine Diphosphate
CNS-Central Nervous System
GA- Ginkgolide A
GB- Ginkgolide B
GC- Ginkgolide C
GM- Ginkgolide M
GJ- Ginkgolide J
GK- Ginkgolide K
BB- Bilobalide

VI. ACKNOWLEDGEMENTS

The authors are thankful to Gujarat State Bio-Technology Mission, Gandhinagar for financial support in the form of Major Research Project FAP-1421(2016) to carry out this research work.

REFERENCES

- [1] K.D. Coder, Ginkgo: Eldest Tree Survivor, 2003.
- [2] Leung AY and Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics. 2 ed. New York: John Wiley & Sons, Inc., 1996.
- [3] Thomson Healthcare. PDR for Herbal Medicines. Montvale, NJ: Thomson Reuters, 2007; 4th, pp.371-384.
- [4] Braquet P., Toqui L., Shen T.Y., Vargaftig F.F., "Perspectives in platelet aggregating factors research", Pharmacological Reviews, 1987; 39, 97-145.
- [5] Beg T, Jyoti S, Naz F, Rahul, Ali F, Ali SK, Reyad AM, Siddique YH. Protective Effect of Kaempferol on the Transgenic Drosophila Model of Alzheimer's Disease. CNS Neurol Disord Drug Targets. 2018;17(6):421-429.
- [6] Shi Y, Wang Y, Wei H. Dantrolene : From Malignant Hyperthermia to Alzheimer's Disease. CNS Neurol Disord Drug Targets. 2018 Jun 19.
- [7] Neelakandan AR, Rajanikant GK. Commentary: Endophenotypes as Disease Modifiers: Decoding the Biology of Alzheimer's by Genome-wide Association Studies. CNS Neurol Disord Drug Targets. 2018 Apr 26;17(1):6-8.
- [8] who report, 2018 March 30. Available from: URL: <http://www.who.int/mediacentre/factsheets/fs362/en>
- [9] AARP Research Report 2016. Better Together: A Comparative analysis of age-friendly and dementia friendly communities. 2018 March 30; Available from: URL: <http://www.aarp.org/content/dam/aarp/livablecommunities/documents-2016/Better-Together-Research-Report.pdf>
- [10] G.M. McKhann, D.S. Knopman, H. Chertkow, et al. the diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's Dement., 2011; 7,263-269.
- [11] Kumar A, Dhawan A, Kadam A, Shinde A. Autophagy and Mitochondria: Targets in Neurodegenerative Disorders. CNS Neurol Disord Drug Targets. 2018;17(9):696-705.
- [12] N. Yadav, R. Yadav, A. Goyal, Chemistry of terpenoids, Int. J. Pharm. Sci. Rev. Res., 2014; 27, 272-278.
- [13] K. Nakanishi. Ginkgolides. Chem. Biol. Pharmacol. Clinic. Perspectives (P. Braquet, ed.), JR Prous Science, 1988; Vol. 1, 27.
- [14] D.J. Carrier, N. Chauret, M. Mancini, et al. Archambault, Detection of ginkgolide A in Ginkgo biloba cell cultures Danielle-Julie, Plant Cell Rep., 1991; 10,256-25.
- [15] R. Banerjee, R. Adhya, A. Thakur, Improvement in binding affinity of Ginkgolide B in comparison to Levodopa: a molecular docking Study, J. Chem. Pharm. Res., 2016; 8(1):729-732.
- [16] S. Pietri, T. Liebgott, J.P. Finet, et al, Synthesis and biological studies of a new ginkgolide C derivative: Evidence that the cardioprotective effect of ginkgolides is unrelated to PAF inhibition, Drug Dev. Res., 2001; 54,191-201.
- [17] S. Bolshakov, S. V. Dzyuba, J. Decatur, K. Nakanishi, A concise synthesis of ginkgolide M, a minor component of a terpene trilactone fraction from Ginkgo biloba roots, J. Nat. Prod., 2006; 69, 429-431.
- [18] Gaussian 16, Revision B.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, et al. Gaussian, Inc., Wallingford CT, 2016.
- [19] GaussView, Version 6, Roy Dennington, Todd A. Keith, and John M. Millam, Semichem Inc., Shawnee Mission, KS, 2016.
- [20] Michel F. Sanner. Python: A Programming Language for Software Integration and Development. J. Mol. Graphics Mod., 1999, Vol 17, February. pp57-61
- [21] Sanner, M.F., Spohner, J.-C., and Olson, A.J. Reduced surface: an efficient way to compute molecular surfaces. Biopolymers, 1996, Vol. 38, (3),305-320.
- [22] Bajaj, C, Park, S., Thane, A., A Parallel Multi-PC Volume Rendering System, ICES and CS Technical Report, University of Texas, 2002.
- [23] Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. and Olson, A. J. Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Computational Chemistry 2009, 16: 2785-91
- [24] Bajaj, C, Pascucci, V., Schikore, D., Fast IsoContouring for Improved Interactivity, Proceedings of ACM Siggraph/IEEE Symposium on Volume Visualization, ACM Press, San Francisco, CA, 1996, 39 - 46,
- [25] Michel F. Sanner, Daniel Stoffler and Arthur J. Olson. ViPER a Visual Programming Environment for Python. 10th International Python Conference, February 2002.
- [26] J. Racine, "The Cygwin tools: a GNU toolkit for Windows," Journal of Applied Econometrics, John Wiley & Sons, Ltd., 2000, vol. 15(3), 331-341.
- [27] Thompson, M. A., Molecular docking using ArgusLab, an efficient shape-based search algorithm and the AScore scoring function. ACS meeting, Philadelphia, 2004; 172, CINF 42, PA.USA
- [28] Bolton E, Wang Y, Thiessen PA, et al. PubChem: integrated platform of small molecules and biological activities. Annu Rep Comput Chem., 2008; 4,217-241.
- [29] Becke, A.D. Density-functional exchange-energy approximation with correct asymptotic behavior. Phys. Rev. A, 1988; 38, 3098-3100.
- [30] Lee, C.; Yang, W.; Parr, R.G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys. Rev. B, 1988; 37, 785-789.
- [31] Becke, A.D. Density-functional thermochemistry. III. The role of exact exchange. J. Chem. Phys., 1993; 98, 5648-5652.
- [32] Berman H. M., Westbrook J, Feng Z, et al. The protein data bank. Nucl Acids Res. 2000; 28,235-242.
- [33] SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep.,2017; 7,42717.
- [34] Seoul, South Corea: Bioinformatics and Molecular Design Research Center; 2004. PreADMET program., accessed 2020 April 10, Available from: URL: <http://preadmet.bmdrc.org>
- [35] Iman K, Mirza MU, Mazhar N, Vanmeert M, Irshad I, Kamal MA. In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer's Disease. CNS Neurol Disord Drug Targets. 2018 Apr 26;17(1):54-68.
- [36] Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev., 2001; 46, 3-26.
- [37] Veber, D.F., Johnson, S.R., Cheng, H., et al. Molecular Properties that Influence the Oral Bioavailability of Drug Candidates. Journal of Medicinal Chemistry, 2002; 45, 2615-2623.
- [38] Oprea, T.I.,Property distribution of drug-related chemical databases*. J. Comput-Aided. Mol. Des., 2000; 14, 251-264.

- [39] Ghose, AK.; Viswanadhan, VN.; Wendoloski JJ.: A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases., *J. Comb. Chem.*, 1999; 1(1), 55-68
- [40] Pardridge, W.M., CNS drug design based on principles of blood-brain barrier transport. *J. Neurochem.*, 1998; 70, 1781-1792.
- [41] Brenk R, Schipani A, James D, et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. *ChemMedChem*, 2008; 3, 435-444.
- [42] Yusof, I. and Segall, M.D. Considering the impact drug-like properties have on the chance of success. *Drug Discov. Today*, 'in press', 2013; 18, 659-666.
- [43] Leeson P. Drug discovery: chemical beauty contest. *Nature.*, 2012; 481,455-456.
- [44] Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J Comput. Chem.*, 1998; 19,1639-1662.
- [45] Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera a visualization system for exploratory research and analysis. *J Comput Chem*, 2004; 25,1605-1612.
- [46] O. Vitolo, B. Gong, Z. Cao, et al. Protection against β -amyloid induced abnormal synaptic function and cell death by Ginkgolide J, *Neurobiol. Aging.*, 2009; 30,257-265.
- [47] Rowe CC, Ng S, Ackermann U, et al., Imaging β -amyloid burden in aging and dementia, *Am. Acad. Neurol.*,2007; 68,1718-1725.
- [48] Shin RW, Iwaki T, Kitamoto T, Tateishi J. Hydrated autoclave pretreatment enhances tau immunoreactivity in formal infixed normal and Alzheimer's disease brain tissues. *Lab Invest.*, 1991; 64,693-702.
- [49] Mirza Z, Rajeh N. Identification of Electrophysiological Changes in Alzheimer's Disease: A Microarray Based Transcriptomics and Molecular Pathway Analysis Study. *CNS Neurol Disord Drug Targets*. 2017;16(9):1027-1038.
- [50] Jiang XW, Lu HY, Xu Z, Liu TY, Wu Q, Yang Y, Zhao QC, Gao HY. In Silico Analyses for Key Genes and Molecular Genetic Mechanism in Epilepsy and Alzheimer's Disease. *CNS Neurol Disord Drug Targets*. 2018;17(8):608-617.
- [51] Singh A, Hasan A, Tiwari S, Pandey LM. Therapeutic Advancement in Alzheimer Disease: New Hopes on the Horizon? *CNS Neurol Disord Drug Targets*. 2018;17(8):571-589
- [52] Khalid R, Noureen N, Kamal MA, Batool S. Computational Protein-Protein docking revealing the therapeutic potential of Kunitz-type Venom against hKv1.2 binding sites. *CNS Neurol Disord Drug Targets*. 2019 Mar 19. doi: 10.2174/1871527318666190319140204. [Epub ahead of print] PubMed PMID: 30892167.
- [53] Kerns, E. and Di, L. Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization. Academic Press, 2008.
- [54] Espinoza LC, Vacacela M, Clares B, Garcia ML, Fabrega MJ, Calpena AC. Development of a Nasal Donepezil-loaded Microemulsion for the Treatment of Alzheimer's Disease: in vitro and ex vivo Characterization. *CNS Neurol Disord Drug Targets*. 2018 Apr 26;17(1):43-53.
- [55] Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. *Nature Biotechnol.* 2014;32, 40-51
- [56] Dahlin, J. L., Inglese, J. & Walters, M. A. Mitigating risk in academic preclinical drug discovery. *Nature Rev. Drug Discov.*2015, 14, 279-294.
- [57] Tian, S. et al. The application of in silico drug-likeness predictions in pharmaceutical research. *Adv Drug Deliv Rev*, 2015,86, 2-10.
- [58] O'Boyle, N. M. et al. OpenBabel: An open chemical toolbox. *J. Cheminform.*2011, 3, 33.
- [59] Ertl, P., Rohde, B. & Selzer, P. Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties. *J. Med. Chem.* 2000, 43, 3714-3717.
- [60] iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. *J. Chem. Inf. Model.*, 2014; 54,3284-3301.
- [61] Wang, R., Fu, Y. & Lai, L. A New Atom-Additive Method for Calculating Partition Coefficients. *J Chem Inf Model*,1997, 37, 615-621.
- [62] Wildman, S. A. & Crippen, G. M. Prediction of Physicochemical Parameters by Atomic Contributions. *J Chem Inf Model*,1999, 39, 868-873.
- [63] Moriguchi, I., Shuichi, H., Nakagome, I. & Hirano, H. Comparison of reliabilityof log P values for Drugs calculated by several methods. *Chem Pharm Bull*, 1994, 42, 976-978.
- [64] Moriguchi, I., Shuichi, H., Liu, Q., Nakagome, I. & Matsushita, Y. Simple Method of Calculating Octanol/Water Partition Coefficient.*Chem. Pharm. Bull.* 1992, 40, 127-130.
- [65] Silicos-IT Log P- FILTER-IT (version 1.0.2) 2013, accessed 2020 April 10; <http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html>
- [66] Mannhold, R., Poda, G. I. & Ostermann, C. Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 compounds. *J. Pharm. Sci.* 2009, 98, 861-893.
- [67] Delaney, J. S. ESOL: Estimating Aqueous Solubility Directly from Molecular Structure. *J Chem Inf Model*. 2004, 44, 1000-1005.
- [68] Ali, J., Camilleri, P., Brown, M. B., Hutt, A. J. & Kirton, S. B. Revisiting the general solubility equation: in silico prediction of aqueous solubility incorporating the effect of topographical polar surface area. *J Chem Inf Model*. 2012, 52, 420-428.
- [69] Montanari, F. & Ecker, G. F. Prediction of drug-ABC-transporter interaction-Recent advances and future challenges. *Adv. Drug Deliv. Rev.* 2015, 86, 17-26.
- [70] Szakács, G., Váradi, A., Ozvegy-Laczka, C. & Sarkadi, B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). *Drug Discov. Today*. 2008, 13, 379-393.
- [71] Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? *Basic Clin Pharmacol Toxicol*. 2005;97:125-134.
- [72] Robert S. Foti and Jan L. Wahlstrom.CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles; *Drug Metabolism and Disposition* March 1, 2008, 36 (3) 523-528
- [73] Dayong Si, Ying Wang, Yi-Han Zhou, Yingjie Guo, Juan Wang, Hui Zhou, Ze-Sheng Li and J. Paul Fawcett; Mechanism of CYP2C9 Inhibition by Flavones and Flavonols; *Drug Metabolism and Disposition* March 1, 2009, 37 (3) 629-634
- [74] Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. "New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme". *Drug Metabolism Reviews*. 2009, 41 (4): 573-643.
- [75] Zhou SF. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4. *Current Pharmaceutical Design*.2008, 14: 990-1000.
- [76] Hollenberg, P. F. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. *Drug Metab. Rev.* 2002, 34, 17-35.

- [77] Huang, S.-M. et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. *J. Clin. Pharmacol.* 2008, 48, 662–670.
- [78] Potts, R. O. & Guy, R. H. Predicting Skin Permeability. *Pharm. Res.* 1992, 09, 663–669.
- [79] Egan, W. J., Merz, K. M. & Baldwin, J. J. Prediction of Drug Absorption Using Multivariate Statistics. *J. Med. Chem.* 2000, 43, 3867–3877.
- [80] Muegge, I., Heald, S. L. & Brittelli, D. Simple selection criteria for drug-like chemical matter. *J. Med. Chem.* 2001, 44, 1841–1846.
- [81] Martin, Y. C. A Bioavailability Score. *J. Med. Chem.* 2005, 48, 3164–3170.
- [82] Baell, J. B. & Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J. Med. Chem.* 2010, 53, 2719–2740.
- [83] Teague, S., Davis, A., Leeson, P. & Oprea, T. The Design of Leadlike Combinatorial Libraries. *Angew. Chem. Int. Ed. Engl.* 1999, 38, 3743–3748.
- [84] Ertl, P. & Schuffenhauer, A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. *J. Cheminform.* 2009, 1, 8.
- [85] Bruce N. Ames, E. G. Gurney, James A. Miller, and H. Bartsch “Carcinogens as Frameshift Mutagens: Metabolites and Derivatives of 2-acetylaminofluorene and other Aromatic Amine Carcinogens”. *PNAS.* 1973, 69: 3128-213
- [86] Pires, D. E. V., Blundell, T. L. & Ascher, D. B. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. *J. Med. Chem.* 2015, 58, 4066–4072.
- [87] Daina, A. & Zoete, V. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. *ChemMedChem.* 2016, 11, 1117–1121.
- [88] Shaikh S, Rizvi SM, Suhail T, Shakil S, Abuzenadah AM, Anis R, Naaz D, Dallol A, Haneef M, Ahmad A, Choudhary L. Prediction of Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study. *CNS Neurol Disord Drug Targets.* 2016;15(10):1216-1221.

10.22214/IJRASET

45.98

IMPACT FACTOR:
7.129

IMPACT FACTOR:
7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089 (24*7 Support on Whatsapp)